Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 14693762.
- Also identified by PMC identifier 1771954.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To report the outcome of topical mitomycin C (MMC) used as adjunctive treatment following primary excision of ocular surface squamous neoplasia (OSSN). Prospective, non-comparative interventional case series of 27 primary OSSN lesions from 26 patients treated in a single ocular oncology centre over a 4 year period. 27 cases of OSSN received a treatment regimen of surgical excision, followed by topical MMC. Mean follow up of 27 (SD 12) months (range 12-50, median 25 months) revealed zero recurrences. MMC treatment following surgical excision decreases the recurrence rate of primary ocular surface neoplasia and should be considered as adjunctive therapy in primary treatment.
Medical subject headings
- Antibiotics, Antineoplastic
- Carcinoma in Situ
- Carcinoma, Squamous Cell
- Eye Neoplasms
- Mitomycin